Phacilitate Leaders Forum

17th - 18th SEPTEMBER 2019



Margarida  Menezes Ferreira

Margarida Menezes Ferreira

Member of the Committee for Advanced Therapies and of the Biologics Working Party, European Medicines Agency (EMA)

Margarida Menezes Ferreira graduated in Biology at the Faculty of Sciences of the University of Lisbon. She had her PhD degree in Medical Biochemistry at the Aix-Marseille II University in France 1981 and did a post-graduate research in molecular endocrinology at the National Institutes of Health USA until 1984. She published several research papers in peer-reviewed journals amongst which two of them were selected for the Year Book of Endocrinology. Since January 1996 she is part of INFARMED, the Portuguese regulatory authority for medicines and health products having developed the strategic plan for the installation of the Biologics, Biotechnology and Microbiology Departments of the National Laboratory for the Control of Medicines and Health Products and coordinated its implementation until 2001. From 1999 to 2001 she was acting Director of the National Control Laboratory for Medicines and Heath Products (OMCL). Since 1999 to the present she has been the INFARMED appointed member of the Biologics Working Party at the European Medicines Agency (EMA).


She has participated in the drafting of European guidance and scientific advice on biological medicinal products including biotechnological and biosimilars as well as gene and cell based therapies. Starting in 2007 as guest member and subsequently as a permanent member of the Cell Products Working Party until its closure, she participated intensely in the construction of the regulatory framework and quality guidance for cell based medicinal products. Presently and since its establishment in 2009 she is the Portuguese member at the Committee for Advanced Therapies. She also collaborates as guest professor with the Faculty of Pharmacy from the University of Lisbon coordinating a chair on Advanced Therapy Medicinal Products. She is also lecturing on Regulatory aspects related to Biotechnology and Advanced Therapy Medicinal Products in several post-graduate courses from Universities of Coimbra and University of Aveiro and at the Instituto Superior Técnico /University of Lisbon in the PhD program MIT-Portugal.


She acted as an expert for the building analytical capacity for laboratory control in the pharmaceutical sector in 2001 at Cape Verde for the World Bank and in 2005 at Angola with the European Commission. Since 1998 she is a member of the National Vaccination Commission; since 2004 she is Member of the Board of the Biotechnology College at the Biologists Association (Colégio de Biotecnologia da Ordem dos Biólogos).

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd